CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and is being developed by a collaboration of Cortex and Shire and Servier. It was researched as a treatment for Alzheimer’s disease under the brand name Ampalex and was also being examined as a treatment for ADHD.
This page contains content from the copyrighted Wikipedia article "CX-516"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
